<DOC>
	<DOCNO>NCT01057498</DOCNO>
	<brief_summary>The purpose study two-fold . First , determine whether nebulized RNS60 safe healthy human subject subject mild asthma , single-dose administration . Second , determine whether nebulized RNS60 safe human subject mild-to-moderate asthma 4-week period .</brief_summary>
	<brief_title>Safety Study Nebulized RNS60 Treat Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>For singledose safety ( Groups 1a 1b ) : 1 . Male female , age 18 65 year . 2.1 . For healthy subject ; clinically consider `` healthy '' diagnosis asthma . 2.2 . For subject mild asthma , clinical diagnosis mild chronic asthma determine National Heart , Lung , Blood Institute 's ( NHLBI ) 2007 guideline , regularly use chronic asthma medication ( &lt; 3 doses/week ) . 3 . Subjects must capable understand purpose risk study provide write , voluntary inform consent . 4 . Women childbearing potential negative pregnancy test ( serum ) time study entry . For multidose safety study ( Group 2e ) : 1 . Male female , age 18 65 year . 2 . Patients clinical diagnosis mild moderate asthma , determine NHLBI 2007 guideline , already use chronic asthma medication . 3 . Historical documentation asthma patient 's medical record . 4 . Men woman reproductive potential document use adequate contraception study 1 month follow last day treatment ( Day 28 ) . 5 . Women childbearing potential negative pregnancy test ( serum ) time study entry . 6 . Subjects , legal guardian , must capable understand purpose risk study provide write , voluntary inform consent . Exclusion Criteria ( group study ) : 1 . With chronic acute disease might interfere evaluation RNS60 therapy . 2 . Pregnancy lactation . 3 . Current prior malignancy ( exclude nonmelanoma skin carcinoma carcinoma situ cervix adequately treat ) . 4 . History infection human immunodeficiency virus ( HIV1 ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) ; Hepatitis A virus ( HAV ) . 5 . Infections require intravenous antibiotic therapy . 6 . Significant organ dysfunction , include cardiac , renal , liver , CNS , pulmonary , vascular , gastrointestinal , endocrine , metabolic ( e.g. , creatinine ≥ 1.6 mg/dL ; ALT AST ≥ 1.5x upper limit normal ; history myocardial infarction , congestive heart failure , arrhythmia within 6 month prior study entry ) . 7 . Treatment humanize chimeric antibody therapy within 4 week prior study entry . 8 . Treatment investigational drug therapy within 4 week prior study entry . 9 . Any use antidepressant psychiatric medicine previous 4 week day . 10 . Group 1b : Any use oral , systemic corticosteroid within 2 week prior enrollment . Group 2e : Any use oral , systemic corticosteroid within 4 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>